1
|
Gakinya S, Mutuiri A, Onyuma T, Cheserem B, Mogere E. Frequency of IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya. Front Med (Lausanne) 2024; 11:1305714. [PMID: 38444421 PMCID: PMC10913195 DOI: 10.3389/fmed.2024.1305714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 01/18/2024] [Indexed: 03/07/2024] Open
Abstract
The 2021 WHO classification of gliomas has separated gliomas based on their IDH mutation status, reflecting differences in their pathogenesis and clinical characteristics. There is a paucity of data on the prevalence of IDH mutations in gliomas in this region. This study aimed to determine the frequency of the IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya. Approximately half of the gliomas were positive for the IDH1 mutation, with a slight male predominance. Our study provides crucial insights into the frequency of IDH1 mutations in gliomas in Kenya.
Collapse
Affiliation(s)
- Samuel Gakinya
- Department of Pathology, Aga Khan University, Nairobi, Kenya
| | | | | | | | - Edwin Mogere
- Department of Pathology, Aga Khan University, Nairobi, Kenya
| |
Collapse
|
2
|
Mutuiri A, Gakinya S. Clinicopathologic features of renal cell carcinomas seen at the Aga Khan University Hospital in Kenya. Front Med (Lausanne) 2022; 9:981305. [DOI: 10.3389/fmed.2022.981305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 10/24/2022] [Indexed: 11/09/2022] Open
Abstract
IntroductionKidney cancer accounted for 1. 8% of global cancer deaths according to Globocan 2020 estimates, with most of these being renal cell carcinomas. Lower rates of renal cell carcinoma are reported for Africa and these are expected to change for a combination of reasons. The clinical and morphologic characteristics of renal cell carcinoma seen within Kenya have not been described before. This study aims to partially fill this gap.Materials and methodsThis was a cross-sectional descriptive study examining electronic histopathology reports from the Aga Khan University Hospital Nairobi Laboratory for the period January 2016 to May 2022.ResultsSixty cases of renal cell carcinoma were identified. The mean age at diagnosis was 55.3 years. The most common histologic subtype diagnosed was clear cell renal cell carcinoma (41.7%), followed by papillary renal cell carcinoma and renal cell carcinoma not further specified (both 21.7%), and chromophobe renal cell carcinoma (11.7%). The most frequent specimen type was resection, followed by cores of renal masses. The mean tumor size was 8.5 cm. Sixty-seven percent of patients presented with Stage III and above.DiscussionRenal masses were the commonest clinical indication for biopsy among the records reviewed. The male to female ratio, as well as the mean age at presentation were comparable to what is described in literature for other regions of the world. The proportions of the commonest histologic subtypes matched what is described in other parts of the world. Challenges in the identification of histologic subtypes included having a limited panel of antibodies for diagnosis and the lack of genetic molecular tests for histotyping.ConclusionThe spectrum of histologic subtypes of renal cell carcinoma seen at a tertiary referral hospital in Nairobi, Kenya was similar to that described in other parts of Africa and the globe. The age at presentation with renal cell carcinoma was consistent with what has been described in literature. Challenges were identified in the accurate histotyping of renal cell carcinoma due to constrained resources. Majority of cases diagnosed presented at advanced stage.
Collapse
|
4
|
Trinkaus ME, Sayed S, Gakinya S, Hanna W, Moloo Z, Rahim Y. External quality assurance of breast cancer pathologic reporting in Kenya. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11586 Background: Eighty percent of women diagnosed with breast cancer (BC) in East Africa present with advanced disease; current literature suggests a preponderance of triple negative/basal like breast cancer in this subset of African women. These studies are limited by their retrospective nature, small numbers, and unclear quality of pathologic specimen reporting. The objective of this study is to provide external quality assurance (EQA), quality control, and validation of hormone receptor and Her2 status of breast cancer specimens from Kenya. Methods: 108 retrospectively identified BC tumour blocks from the Aga Khan University Hospital (Nairobi, Kenya) during 2006–2008 will undergo repeat pathologic assessment for estrogen receptor (ER), progesterone receptor (PR), and Her2 status at Sunnybrook Health Sciences Center (Toronto, Canada).Currently at the Aga Khan University Pathology Lab, ER,PR and Her2 testing is performed manually once every two weeks using Heat Induced Antigen Retrieval and Dako reagents including the ENVISION detection system. Parallel controls of known tissue reactivity are also run; however there is currently no formal EQA. Results: Results will be used to identify areas of improvement in specimen handling and pathology reporting. Conclusions: Standardized and accurate pathologic assessment of BC specimens in East Africa is essential for establishing centres of excellence in Kenya and the wider East African region for hormone receptor and Her2 neu analysis. Results would contribute to understanding the prevalence of triple negative disease in East Africa, lead to improved treatment recommendations and patient outcomes, and serve as a foundation for prospective studies in East Africa. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. E. Trinkaus
- Princess Margaret Hospital, Toronto, ON, Canada; Aga Khan University Hospital, Nairobi, Kenya; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto East General Hospital, Toronto, ON, Canada
| | - S. Sayed
- Princess Margaret Hospital, Toronto, ON, Canada; Aga Khan University Hospital, Nairobi, Kenya; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto East General Hospital, Toronto, ON, Canada
| | - S. Gakinya
- Princess Margaret Hospital, Toronto, ON, Canada; Aga Khan University Hospital, Nairobi, Kenya; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto East General Hospital, Toronto, ON, Canada
| | - W. Hanna
- Princess Margaret Hospital, Toronto, ON, Canada; Aga Khan University Hospital, Nairobi, Kenya; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto East General Hospital, Toronto, ON, Canada
| | - Z. Moloo
- Princess Margaret Hospital, Toronto, ON, Canada; Aga Khan University Hospital, Nairobi, Kenya; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto East General Hospital, Toronto, ON, Canada
| | - Y. Rahim
- Princess Margaret Hospital, Toronto, ON, Canada; Aga Khan University Hospital, Nairobi, Kenya; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto East General Hospital, Toronto, ON, Canada
| |
Collapse
|